Skip to main content
. 2024 Sep 10;14:1428464. doi: 10.3389/fonc.2024.1428464

Table 2.

Anti-infective prophylaxis in patients with CLL on ibrutinib.

Prophylaxis Recommended
YES NO
Antibacterial graphic file with name fonc-14-1428464-i001.jpg
PJP graphic file with name fonc-14-1428464-i006.jpg
Antiviral graphic file with name fonc-14-1428464-i007.jpg
HBV ( HBsAg+) graphic file with name fonc-14-1428464-i001.jpg
HBV(HBsAg-/anti-HBc+) graphic file with name fonc-14-1428464-i008.jpg graphic file with name fonc-14-1428464-i008.jpg
Antifungal graphic file with name fonc-14-1428464-i001.jpg

*In specific high-risk cases should be considered.

**Selected patients with specific risk factors may be considered for aciclovir prophylaxis during the first 6 months of ibrutinib treatment.

***Both prophylactic treatment and monitoring are accepted.